Novavax reported $643.85M in Operating Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Adamas Pharmaceuticals ADMS:US 31.13M 2.29M
Adma Biologics ADMA:US $ 33.41M 2.2M
Agenus AGEN:US $ 77.12M 24.04M
AstraZeneca AZN:LN 7.09B 1.67B
Astrazeneca AZN:US 7.09B 1.67B
Biocryst Pharmaceuticals BCRX:US $ 79.54M 9.1M
BioSpecifics Technologies BSTC:US 4.74M 589.61K
Dynavax Technologies DVAX:US $ 48.83M 5.98M
Genocea Biosciences GNCA:US $ 14.55M 2.12M
Geron GERN:US $ 29M 405K
GlaxoSmithKline GSK:LN 6.42B 692M
Kindred Biosciences KIN:US 12.08M 520K
Mannkind MNKD:US $ 55.68M 32.06M
Merk MRK:US $ 9905M 839M
Minerva Neurosciences NERV:US $ 8.96M 1.46M
Moderna Inc MRNA:US 1.29B 621M
Novartis NVS:US 9.82B 464M
Novavax NVAX:US $ 643.85M 12.01M
Pain Therapeutics PTIE:US $ 5.14M 1.6M
Peregrine Pharmaceuticals PPHM:US $ 23.82M 695K
Pfizer PFE:US $ 13063M 3998M
Sarepta Therapeutics SRPT:US $ 331.66M 32.87M
Tg Therapeutics TGTX:US $ 79.04M 10.96M